FILTER
FILTERED INTERVIEW RESULTS
Luca Candioli
OWNER & GENERAL MANAGER, CANDIOLI PHARMA
Italian animal health company Candioli explains how it intends to double in size during the next five years.
Paolo Tubertini
CEO, OLON
Olon has expanded from production of APIs and intermediates to include CDMO and Biotech operations in Italy and beyond.
Salvatore Butti
PRESIDENT, ASSOSALUTE - FEDERCHIMICA
Assosalute represents non-prescription medical products in Italy and explains how easing regulations could be of huge benefit to Italians and the healthcare system.
Paolo Russolo
PRESIDENT, ASCHIMFARMA – FEDERCHIMICA
Aschimfarma explains to GBR how Italian producers of APIs are well positioned to strengthen the European drug supply chain.
Enrique Häusermann
PRESIDENT, ASSOCIAZIONE NAZIONALE INDUSTRIE FARMACI GENERICI E BIOSIMILARI (ASSOGENERICI)
Assogenerici is the Italian association that represents the country’s generic and biosimilar pharmaceutical industry.
Paolo Russolo
PRESIDENT, ASCHIMFARMA
Aschimfarma represents Italian producers of pharmaceutical ingredients and helps advise them on regulations across the world.
Dario Piola
GENERAL MANAGER, TUBIFLEX
Tubiflex offers innovative fluid circulation products for both the aerospace and automotive industries and has recently been acquired by the Interpump Group.
Matteo Bertolloti, CEO, Ing. Bertolloti
CEO, ING. BERTOLLOTI
Ing. Bertolloti is typical of many of the SMEs that make up the Italian aerospace sector in its eagerness to collaborate with other companies and to extend business internationally.
Marco Casucci
MANAGING DIRECTOR, INTECS SOLUTIONS
Intecs Solutions develops innovative security systems for civil and military applications.
Alberto Veneruso
MANAGING DIRECTOR, GEVEN FEBRUARY 2, 2017
Geven is expanding the customer base for its aircraft passenger seats and increasing manufacturing capacity to meet the growing demand.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
